At Novo Nordisk, our R&D pipeline reflects our long-standing
commitment to driving change to defeat diabetes and other serious
chronic conditions.
Our scientists are currently working on novel and innovative treatments to address the unmet needs of people living with diabetes, obesity, cardiovascular disease, haemophilia, growth disorders and non-alcoholic steatohepatitis (NASH).
Explore our pipeline
Browse our entire R&D pipeline by study phase, or select a specific therapy areas. Click on a candidate to access up-to-date trial information.
